NASDAQ
22.05.26 | 21:59
3,545 US-Dollar
-0,42 % -0,015
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12.05. | C4 Therapeutics GAAP EPS of -$0.20 beats by $0.06, revenue of $6.15M beats by $1.73M | 1 | Seeking Alpha | ||
| 12.05. | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | 215 | GlobeNewswire (Europe) | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| 12.05. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.05. | C4 Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.04. | Roche places a $1bn bet on C4T degrader-antibody conjugates | 9 | pharmaphorum | ||
| 10.04. | Roche and C4 Therapeutics to advance degrader-antibody conjugates research | 7 | Pharmaceutical Technology | ||
| 10.04. | Roche kehrt mit Degrader-Deal zu C4 Therapeutics zurück | 29 | transkript.de | ||
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.04. | C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies | 14 | Benzinga.com | ||
| 09.04. | C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates | 6 | Seeking Alpha | ||
| 09.04. | C4 Therapeutics Enters Collaboration Agreement With Roche | 490 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - C4 Therapeutics (CCCC) has entered into a new collaboration agreement with Roche (RHHBY, RO.SW, ROG.SW) to advance research in the degrader-antibody conjugate... ► Artikel lesen | |
| 09.04. | C4 Therapeutics, Roche partner on cancer degrader conjugates | 12 | Investing.com | ||
| 09.04. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 25.03. | C4 Therapeutics, Inc.: C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma | 366 | GlobeNewswire (Europe) | WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 25.03. | Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock | 2 | Insider Monkey | ||
| 09.03. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 26.02. | Barclays raises C4 Therapeutics stock price target on trial progress | 9 | Investing.com | ||
| 26.02. | TD Cowen reiterates Buy rating on C4 Therapeutics stock | 1 | Investing.com | ||
| 26.02. | TD Cowen bestätigt "Buy"-Rating für C4 Therapeutics nach starkem Kursanstieg | 2 | Investing.com Deutsch | ||
| 26.02. | C4 Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,176 | +2,08 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,146 | -1,88 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 26,490 | 0,00 % | Celldex Therapeutics, Inc.: Celldex Reports First Quarter Financial Results and Provides Corporate Update | Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,457 | -5,27 % | Cardiff Oncology kündigt Webcast zu neuen Studiendaten für Krebsmedikament an | ||
| COHERUS ONCOLOGY | 1,423 | +2,23 % | Coherus BioSciences: Umsatz verfehlt Prognose und sorgt für verhaltenen Ausblick | ||
| ARCTURUS THERAPEUTICS | 7,040 | +0,14 % | Arcturus outlines 12-week ARCT-032 Phase II enrollment and extends cash runway beyond Q2 2028 | ||
| NEOVACS | 0,000 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.05.2026 | Das Instrument POH3 US14365C1036 CARNIVAL PLC ADR/1 DL1,66 EQUITY wird cum Kapitalmassnahme gehandelt am 06.05.2026 und ex Kapitalmassnahme am 07.05.2026 The instrument POH3 US14365C1036 CARNIVAL PLC... ► Artikel lesen | |
| ULTRAGENYX | 20,270 | +1,94 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| GYRE THERAPEUTICS | 5,200 | -0,95 % | Gyre Therapeutics Inc.: Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update | Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 6,060 | -0,66 % | Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade | ||
| GOSSAMER BIO | 0,180 | -1,37 % | Gossamer Bio: Umsatz übertrifft Erwartungen deutlich, Aktie nach Gewinnverfehlung unter Druck | ||
| BIOMEA FUSION | 1,425 | +0,35 % | Biomea Fusion, Inc.: Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights | Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used... ► Artikel lesen | |
| JANUX THERAPEUTICS | 14,520 | 0,00 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SOLID BIOSCIENCES | 6,630 | +0,15 % | Solid Biosciences Inc.: Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates | - Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 8,605 | +0,06 % | 4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data... ► Artikel lesen |
Das Unternehmen C4 THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,545 Euro und damit -0,42 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.